文献速递炎症性肠病

单基因炎症性肠病的系统综述

A Systematic Review of Monogenic Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-03-18

最常见的基因为IL10RA/B、XIAP、CYBB、LRBA和TTC7A,63.4%的患者在6岁前发病,76.0%在病程中出现至少1种肠外合并症,接受手术、生物制剂和造血干细胞移植的比例分别为27.1%、32.9%和23.1%。

要点

  • 单基因IBD虽罕见,但肠外合并症多样且治疗选择有限。
  • 多数单基因IBD在6岁前发病,不同年龄组基因谱差异显著。
  • 早期识别和了解基因及疾病过程对有效管理至关重要。

核心结论

  • 单基因IBD病例虽罕见,但肠外合并症表现多样,治疗选择有限,包括手术和移植。
  • 早期识别并加深对单基因IBD相关基因及潜在疾病过程的理解对有效管理十分重要。

研究设计与样本

  • 从303篇符合条件的文章中识别出750例单基因IBD病例。

主要发现

  • 最常报告的单基因IBD基因为IL10RA/B、XIAP、CYBB、LRBA和TTC7A。
  • 63.4%的患者在6岁前发生IBD,17.4%在10至17.9岁之间发生,10.9%在18岁后发生。
  • 仅31.7%的患者在IBD发病前有肠外合并症(EIC)病史,但76.0%在临床病程中发生至少1种EIC。
  • 最常见的EIC为非典型感染(44.7%)、皮肤异常(38.4%)和自身免疫(21.9%)。
  • 分别有27.1%、32.9%和23.1%的患者接受了肠道手术、生物制剂治疗和造血干细胞移植。

关键数值与推荐

  • 单基因IBD患者中,63.4%在6岁前发病,17.4%在10至17.9岁发病,10.9%在18岁后发病。
  • 31.7%的患者在IBD发病前有EIC病史,76.0%在病程中发生至少1种EIC。
  • 最常见EIC为非典型感染(44.7%)、皮肤异常(38.4%)和自身免疫(21.9%)。
  • 27.1%接受肠道手术,32.9%接受生物制剂治疗,23.1%接受造血干细胞移植。

临床怎么用

  • 对早发IBD患者应警惕单基因病因,关注IL10RA/B、XIAP、CYBB、LRBA和TTC7A等基因。
  • 临床管理中需监测并处理多样化的肠外合并症,如非典型感染、皮肤异常和自身免疫。
  • 治疗选择包括手术、生物制剂和造血干细胞移植,需根据基因和疾病过程个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Advances in genomic technologies have led to increasing reports of monogenic inflammatory bowel disease (IBD). Here, we systematically review the literature to determine the clinical features, genetic profile, and previously used treatment strategies in monogenic IBD. METHODS: A systematic review of MEDLINE articles published between January 2000 and December 2020 was conducted. A total of 750 individual monogenic IBD cases were identified from 303 eligible articles. RESULTS: The most frequently reported monogenic IBD genes were IL10RA/B, XIAP, CYBB, LRBA, and TTC7A. In total, 63.4% of patients developed IBD before 6 years of age, 17.4% developed IBD between ages 10 and 17.9 years, and 10.9% developed IBD after age 18. There was a substantial difference between these age groups and the underlying monogenic disorders. Only 31.7% had any history of extraintestinal comorbidity (EIC) before IBD onset, but 76.0% developed at least 1 EIC during their clinical course. The most common EICs were atypical infection (44.7%), dermatologic abnormality (38.4%), and autoimmunity (21.9%). Bowel surgery, biologic therapy, and hematopoietic stem cell transplantation were performed in 27.1%, 32.9%, and 23.1% of patients, respectively. CONCLUSIONS: Monogenic IBD cases, although rare, have varied extraintestinal comorbidities and limited treatment options including surgery and transplant. Early identification and improved understanding of the characteristics of the genes and underlying disease processes in monogenic IBD is important for effective management.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Nambu R, Warner N, Mulder DJ, et al. A Systematic Review of Monogenic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2021. PMID: 33746097. doi:10.1016/j.cgh.2021.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。